Anti-MSLN CD8+ T cell responses were detected in 36% of cancer patients (9 out of 25), 20% of benign pancreatic disease patients (3 out of 15) and in only 6.3% of healthy controls (1 out of 16). This evidence concerns the gene CD8A and cancer.